Inventor · disambiguated record
Noubar B. Afeyan
Also filed as: AFEYAN NOUBAR B · AFEYAN NOUBAR BOGHOS
21 granted patents·41 pending applications·276 citations·filing 2008–2025
96Inventor score
Files withRUBIUS THERAPEUTICS INC32JOULE UNLTD TECHNOLOGIES INC5FLAGSHIP PIONEERING INC4FLAGSHIP PIONEERING INNOVATIONS V INC4BERRY DAVID ARTHUR3
Top patents by PatentIndex Score
62 records- 0198US9644180B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2015·Granted May 9, 2017·98 cites·21 claims
- 0297US10344263B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jul 9, 2019·14 cites·25 claims
- 0397US10329531B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·18 cites·29 claims
- 0497US10253296B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·16 cites·24 claims
- 0597US7981647B2Engineered CO2 fixing microorganisms producing carbon-based products of interestJOULE UNLTD INC·Filed 2009·Granted Jul 19, 2011·43 cites·9 claims
- 0696US10301594B1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·11 cites·29 claims
- 0795US10301593B2Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Granted May 28, 2019·8 cites·27 claims
- 0894US10456421B2Compositions and methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·10 cites·20 claims
- 0994US7785861B2Hyperphotosynthetic organismsJOULE UNLTD INC·Filed 2008·Granted Aug 31, 2010·20 cites·16 claims
- 1093US10869898B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2015·Granted Dec 22, 2020·6 cites·25 claims
- 1193US8048654B2Methods and compositions for the recombinant biosynthesis of fatty acids and estersJOULE UNLTD TECHNOLOGIES INC·Filed 2010·Granted Nov 1, 2011·12 cites·13 claims
- 1292US10557119B2Erythroid cells comprising phenylalanine ammonia lyaseRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 11, 2020·4 cites·27 claims
- 1392US10517897B1Methods related to engineered erythoid cells comprising 4-1BBLRUBIUS THERAPEUTICS INC·Filed 2019·Granted Dec 31, 2019·4 cites·28 claims
- 1490US10568910B2Compositions and methods related to engineered erythroid cells comprising IL-15RUBIUS THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·18 claims
- 1588US8227237B2Engineered CO2 fixing microorganisms producing carbon-based products of interestREPPAS NIKOS B·Filed 2011·Granted Jul 24, 2012·6 cites·20 claims
- 1684US9150888B2Engineered CO2 fixing microorganisms producing carbon-based products of interestBERRY DAVID ARTHUR·Filed 2012·Granted Oct 6, 2015·2 cites·12 claims
- 1783US2023293588A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer IndicationsRUBIUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1878US2022072048A1Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune IndicationsRUBIUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1975US10716811B2Compositions and methods related to multimodal therapeutic cancer indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jul 21, 2020·0 cites·20 claims
- 2075US8399227B2Methods and compositions for the recombinant biosynthesis of fatty acids and estersBERRY DAVID ARTHUR·Filed 2011·Granted Mar 19, 2013·1 cites·14 claims
- 2175US2020002674A1Erythroid cells comprising phenylalanine hydroxylaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2275US2019309262A1Erythroid cells comprising serine dehydrataseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2375US2019309261A1Erythroid cells comprising lysine oxidaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2475US2019316091A1Erythroid cells comprising arginaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2575US2019376034A1Platelets comprising exogenous polypeptides and uses thereofRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2675US2019316090A1Erythroid cells comprising arginine deiminaseRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2774US2019388473A1Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2872US2018216067A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2972US2018265847A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3071US2015182588A1Synthetic membrane-receiver complexesVL26 INC·Filed 2014·Application pending·0 cites
- 3171US2020129556A1Compositions and methods related to engineered erythroid cells comprising il-15RUBIUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3271US2018187153A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3371US2018187154A1Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3470US2018187155A1Compositions and methods related to multimodal therapeutic cell systems for autoimmune indicationsRUBIUS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3569US2021177823A1Neuromodulating compositions and related therapeutic methods for the treatment of cancerFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 3669US2021154272A1Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune responseFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2020·Application pending·0 cites
- 3769US2015082691A1Methods and Compositions for the Recombinant Biosynthesis of Fatty Acids and EstersJOULE UNLTD TECHNOLOGIES INC·Filed 2014·Application pending·0 cites
- 3866US11576934B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2019·Granted Feb 14, 2023·0 cites·20 claims
- 3966US2016257932A1Genetically engineered enucleated erythroid cells comprising a phenylalanine ammonia lyase receiver polypeptideRUBIUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4066US2023203158A1Methods for modulating intestine cells or tissue functionFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2022·Application pending·0 cites
- 4163US11554141B2Methods and compositions for immunomodulationRUBIUS THERAPEUTICS INC·Filed 2018·Granted Jan 17, 2023·0 cites·18 claims
- 4262US8906665B2Methods and compositions for the recombinant biosynthesis of fatty acids and estersBERRY DAVID ARTHUR·Filed 2013·Granted Dec 9, 2014·0 cites·20 claims
- 4362US2021283217A1Neuromodulating compositions and related therapeutic methods for the treatment of inflammatory and autoimmune diseasesFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2017·Application pending·0 cites
- 4462US2025353906A1Compositions and methods for targeted delivery of therapeutic agentsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2023·Application pending·0 cites
- 4560US2009191599A1Engineered light-harvesting organismsJOULE BIOTECHNOLOGIES INC·Filed 2008·Application pending·0 cites
- 4659US2013273613A1Hyperphotosynthetic OrganismsJOULE UNLTD TECHNOLOGIES INC·Filed 2013·Application pending·0 cites
- 4759US2019240293A1Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune responseFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2017·Application pending·0 cites
- 4858US2024336945A1Trem compositions and uses thereofFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 4956US2025163151A1Methods for modulating intestine cells or tissue functionFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2025·Application pending·0 cites
- 5056US2009047295A1Methods and Compositions for Reducing Stemness in OncogenesisBERRY DAVID A·Filed 2008·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Noubar B. Afeyan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →